• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受血液透析的5期慢性肾脏病患者的认知功能:与标准磷结合剂治疗相比,碳酸镧无不良影响。

Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.

作者信息

Altmann P, Barnett M E, Finn W F

机构信息

Oxford Kidney Unit, Oxford Radcliffe Hospitals NHS Trust and University of Oxford, Oxford, UK.

出版信息

Kidney Int. 2007 Feb;71(3):252-9. doi: 10.1038/sj.ki.5001932. Epub 2006 Oct 11.

DOI:10.1038/sj.ki.5001932
PMID:17035945
Abstract

Patients with Stage 5 chronic kidney disease who have hyperphosphatemia require treatment with phosphate binders to lower serum phosphorus levels. Existing binders are effective but may be associated with important safety disadvantages. Lanthanum carbonate is a phosphate binder with demonstrated efficacy, safety, and tolerability in clinical trials. Changes in cognitive function were evaluated over time using the Cognitive Drug Research computerized cognitive assessment system (Simple Reaction Time, Digit Vigilance Task, Choice Reaction Time, Numeric Working Memory, and Delayed Picture Recognition) in 360 hemodialysis patients who were enrolled in a 2-year, multicenter, comparative study of lanthanum carbonate versus standard therapy. A decline in cognitive function from baseline was observed in both groups. The deterioration in cognitive function was similar in both the lanthanum carbonate and standard therapy groups. One parameter - Numeric Working Memory - showed a statistically significant between-group difference in favor of lanthanum carbonate (P=0.02). Given the magnitude of the changes, however, and the differences that were observed at baseline between treatment groups, the clinical significance of this difference is doubtful. This study demonstrates that cognitive function deteriorates in hemodialysis patients over a 2-year time period. Use of lanthanum carbonate as a phosphate binder does not adversely affect cognitive function compared with standard therapy.

摘要

患有5期慢性肾脏病且伴有高磷血症的患者需要使用磷结合剂进行治疗,以降低血清磷水平。现有的磷结合剂虽有疗效,但可能存在一些严重的安全缺陷。碳酸镧是一种磷结合剂,在临床试验中已证明其有效性、安全性和耐受性。在一项为期2年的多中心碳酸镧与标准疗法对比研究中,对360名接受血液透析的患者使用认知药物研究计算机化认知评估系统(简单反应时间、数字警觉任务、选择反应时间、数字工作记忆和延迟图片识别),随时间评估认知功能变化。两组均观察到认知功能较基线水平下降。碳酸镧组和标准疗法组的认知功能恶化情况相似。一个参数——数字工作记忆——显示两组间存在统计学显著差异,碳酸镧组更具优势(P = 0.02)。然而,鉴于变化幅度以及治疗组间在基线时观察到的差异,这种差异的临床意义存疑。本研究表明,血液透析患者的认知功能在2年期间会恶化。与标准疗法相比,使用碳酸镧作为磷结合剂不会对认知功能产生不利影响。

相似文献

1
Cognitive function in Stage 5 chronic kidney disease patients on hemodialysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.接受血液透析的5期慢性肾脏病患者的认知功能:与标准磷结合剂治疗相比,碳酸镧无不良影响。
Kidney Int. 2007 Feb;71(3):252-9. doi: 10.1038/sj.ki.5001932. Epub 2006 Oct 11.
2
A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis.一项关于新型磷结合剂碳酸镧治疗接受血液透析患者安全性的长期开放标签扩展研究。
Curr Med Res Opin. 2005 May;21(5):657-64. doi: 10.1185/030079905X41453.
3
One year efficacy and safety of lanthanum carbonate for hyperphosphatemia in Japanese chronic kidney disease patients undergoing hemodialysis.碳酸镧对日本接受血液透析的慢性肾病患者高磷血症的一年疗效及安全性
Ther Apher Dial. 2010 Feb;14(1):12-9. doi: 10.1111/j.1744-9987.2009.00697.x.
4
Multicenter prospective randomized, double-blind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.在日本高磷血症血液透析患者中,碳酸镧与碳酸钙作为磷结合剂的多中心前瞻性随机双盲对照研究。
Clin Nephrol. 2008 Nov;70(5):404-10. doi: 10.5414/cnp70404.
5
Assessment of survival in a 2-year comparative study of lanthanum carbonate versus standard therapy.评估碳酸镧与标准疗法 2 年对照研究中的生存情况。
Curr Med Res Opin. 2009 Dec;25(12):3021-8. doi: 10.1185/03007990903399398.
6
Randomized, double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia.一项随机、双盲、安慰剂对照、剂量滴定的III期研究,评估碳酸镧(一种用于治疗高磷血症的新型磷结合剂)的疗效和耐受性。
Am J Kidney Dis. 2003 Jul;42(1):96-107. doi: 10.1016/s0272-6386(03)00554-7.
7
Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients.碳酸镧与标准疗法治疗高磷血症:慢性维持性血液透析患者的安全性和疗效
Clin Nephrol. 2006 Mar;65(3):191-202. doi: 10.5414/cnp65191.
8
Safety and efficacy evaluation of lanthanum carbonate for hyperphosphatemia in end-stage renal disease patients.碳酸镧用于终末期肾病患者高磷血症的安全性和有效性评估。
Contrib Nephrol. 2015;185:42-55. doi: 10.1159/000380969. Epub 2015 May 19.
9
Lanthanum carbonate--a first line phosphate binder?
Semin Dial. 2007 Jul-Aug;20(4):325-8. doi: 10.1111/j.1525-139X.2007.00301.x.
10
Lanthanum carbonate (Fosrenol) efficacy and tolerability in the treatment of hyperphosphatemic patients with end-stage renal disease.碳酸镧(福斯利诺)治疗终末期肾病高磷血症患者的疗效和耐受性。
Clin Nephrol. 2005 Jun;63(6):461-70. doi: 10.5414/cnp63461.

引用本文的文献

1
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2025 Jun 27;6(6):CD006023. doi: 10.1002/14651858.CD006023.pub4.
2
Endothelium-related biomarkers and cognitive decline in prevalent hemodialysis patients: A prospective cohort study.在现患血液透析患者中与内皮相关的生物标志物与认知能力下降:一项前瞻性队列研究。
Eur J Neurol. 2024 Dec;31(12):e16438. doi: 10.1111/ene.16438. Epub 2024 Aug 13.
3
Changes in measures of cognitive function in patients with end-stage kidney disease on dialysis and the effect of dialysis vintage: A longitudinal cohort study.
透析终末期肾病患者认知功能测量的变化及透析时间的影响:一项纵向队列研究。
PLoS One. 2021 May 25;16(5):e0252237. doi: 10.1371/journal.pone.0252237. eCollection 2021.
4
Interventions to Preserve Cognitive Functioning Among Older Kidney Transplant Recipients.老年肾移植受者认知功能保护干预措施。
Curr Transplant Rep. 2020 Dec;7(4):346-354. doi: 10.1007/s40472-020-00296-w. Epub 2020 Oct 21.
5
Interventions Made to Preserve Cognitive Function Trial (IMPCT) study protocol: a multi-dialysis center 2x2 factorial randomized controlled trial of intradialytic cognitive and exercise training to preserve cognitive function.干预以保留认知功能试验(IMPCT)研究方案:一项多透析中心 2x2 析因随机对照试验,旨在通过透析中认知和运动训练来保留认知功能。
BMC Nephrol. 2020 Sep 3;21(1):383. doi: 10.1186/s12882-020-02041-y.
6
Exercise and cognitive function in patients with end-stage kidney disease.终末期肾病患者的运动与认知功能
Semin Dial. 2019 Jul;32(4):283-290. doi: 10.1111/sdi.12804. Epub 2019 Mar 22.
7
Lanthanum carbonate, a phosphate binder, inhibits calcification of implanted aortic allografts in a rat model.碳酸镧是一种磷结合剂,在大鼠模型中可抑制植入的主动脉同种异体移植物的钙化。
Gen Thorac Cardiovasc Surg. 2019 May;67(5):413-419. doi: 10.1007/s11748-018-1026-7. Epub 2018 Oct 29.
8
Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD).用于预防和治疗慢性肾脏病-矿物质和骨异常(CKD-MBD)的磷结合剂。
Cochrane Database Syst Rev. 2018 Aug 22;8(8):CD006023. doi: 10.1002/14651858.CD006023.pub3.
9
Intradialytic Cognitive and Exercise Training May Preserve Cognitive Function.透析期间认知与运动训练可能保留认知功能。
Kidney Int Rep. 2017 Aug 19;3(1):81-88. doi: 10.1016/j.ekir.2017.08.006. eCollection 2018 Jan.
10
A Review of Phosphate Binders in Chronic Kidney Disease: Incremental Progress or Just Higher Costs?慢性肾脏病中磷结合剂的研究进展:是增量进步还是仅仅增加了成本?
Drugs. 2017 Jul;77(11):1155-1186. doi: 10.1007/s40265-017-0758-5.